Qi Liu‡
ab,
Wenhua Lu‡a,
Mingzhe Maa,
Jianwei Liaoa,
A. Ganesanc,
Yumin Hua,
Shijun Wen*ab and
Peng Huanga
aSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou 510060, China. E-mail: wenshj@sysucc.org.cn
bSchool of Pharmaceutical Sciences, Sun Yat-sen University, 132 Waihuan East Road, Guangzhou 510006, China
cSchool of Pharmacy, University of East Anglia, Norwich NR4 7TJ, UK
First published on 26th November 2014
Santacruzamate A, a recently discovered natural product from a Panamanian marine cyanobacterium Symploca sp., features a similar structure to the clinically used histone deacetylase (HDAC) inhibitor vorinostat (SAHA). We have synthesized the natural product and a small set of analogues for SAR studies. To our surprise, the synthetic natural product santacruzamate A (1a) and the analogues did not show an obvious inhibition even at 2 μM in HDAC enzyme assays while the IC50 value was 0.12 nM in the original report. However, a novel compound, 5, containing a terminal thiourea motif was found to inhibit the growth of malignant cells at submicromolar concentrations. Moreover, 5 was not cytotoxic to normal human colonic epithelial cells CCD841, suggesting that its cytotoxicity was specific to cancer cells. Further investigation indicated that the compound induced apoptosis, affected cell cycle progression and increased ROS production. We believe its mechanism of action is unrelated to HDAC inhibition and the original activity reported for santacruzamate needs to be reevaluated.
Nature has been continuously providing humans with important leads and natural product medicines for the treatment of a wide spectrum of diseases.10–12 Natural products have been a particularly important source of anticancer chemotherapeutic medicines including taxanes, Vinca alkaloids and camptothecin that act upon the mitotic spindle.13 This trend is likely to continue as natural products are identified that modulate specific signaling pathways in cells. One example is the relatively new field of epigenetics relating to chromatin modelling via structural modifications of the DNA and histone proteins. A variety of natural products have already been reported that inhibit the enzymes involved in epigenetics.14 Among these, the histone deacetylase (HDAC) family of enzymes has received much attention. HDACs are the enzymes that hydrolyse acetyl-lysine amino acid residues in proteins back to lysine and play crucial roles in diverse cellular functions, while their overexpression or mutation is widely observed in cancer cells.15–17 A number of potent natural product HDAC inhibitors such as trichostatin A and apicidin are used as biological tools while the depsipeptide FK228 (romidepsin) has received FDA approval for the treatment of cutaneous T-cell lymphoma (CTCL).
Recently, Balunas and co-workers reported the isolation of santacruzamate A (1a) from a marine Panamanian cyanobacterium resembling the genus Symploca.18 Santacruzamate A shares some structural similarity with the synthetic HDAC inhibitor vorinostat (SAHA), the first clinically approved drug in this class (Fig. 1). It was reported that santacruzamate A specifically inhibited the isoform HDAC2 with an IC50 of 0.12 nM. This was a surprising result given the established SAR of HDAC inhibitors in which a zinc-binding group, such as the hydroxamic acid in vorinostat, is important for reversible binding to the enzyme active site.19 Instead, santacruzamate A contains a carbamate and amide-functional groups that have not been previously associated with potent HDAC inhibition. The natural product azumamide A, for example, contains a carboxamide zinc-binding group and is only micromolar in HDAC inhibition.20,21 Furthermore, the high selectivity of santacruzamate A for HDAC2 was intriguing as SAHA itself is a non-selective inhibitor active against both Class I and Class II HDAC isoforms. With this background, it was of interest to synthesize santacruzamate A as well as a series of analogues to investigate the structure–activity relationships (SAR) of this new lead or the development of anticancer agents. This has led to the identification of a potent cytotoxic compound 5 that we nevertheless believe acts by a HDAC-independent mechanism of action.
To investigate the importance of the linker in santacruzamate A between the carbamate and amide structural features, our SAR strategy was to move around the position of the amide and also to replace the terminal ethoxycarbonyl group with other bioisosteric functional groups. Thus, a series of compounds were designed and prepared alongside with the natural product santacruzamate A itself (1a) (Fig. 2).
The synthetic route to obtain these compounds is shown in Scheme 1. Conventional acylation of the terminal amino groups of commercial available amino acids 6 with ethyl chloroformate gave compounds 7a–d, while protection of 6c with di(tert-butyl) carbonate (Boc2O) afforded 8. Amidation of the carboxylic acid groups of 7a–d and 8 with amines or aniline afforded the desired target products 1a–d, 2 and 3. After removal of the Boc group from 3 under acidic conditions, the obtained free amine 9 underwent subsequent treatment with either isocyanatoethane or ethyl isothiocyanate to give two additional analogues 4 and 5.
After the synthesis of the designed compounds 1a–d, and 3–5, they were subsequently screened for their cellular biological activity. To our surprise, synthetic santacruzamate A, i.e. 1a did not show cytotoxicity against human colon cancer cells HCT-116 even at 100 μM while most of the other synthetic analogues were inactive (Table 1). However, compound 5 inhibited the growth of HCT-116 cells and human myeloblastic leukemia cells ML-1 with IC50 values of 6.0 and 9.4 μM. To our delight, 5 was not cytotoxic to normal cells (CCD841) even at 100 μM. Indeed, it is high desirable to obtain a compound with a high selectivity to kill malignant cancer cells because most of clinical anticancer drug also kill normal cells during therapeutical treatment. For example, SAHA was very cytotoxic to CCD841 cells at 20 μM although with its lower IC50 value to cancer cells.
Compound | IC50a (μM) ± SEM | ||
---|---|---|---|
HCT-116 | ML-1 | CCD841 | |
a IC50 is the drug concentration effective in inhibiting 50% of the cell growth measured by the MTS assay. NT, not tested. | |||
1a | >100 | >100 | NT |
1b | 90.8 ± 6.9 | >100 | NT |
1c | >100 | >100 | NT |
1d | 94.3 ± 13.8 | >100 | NT |
2 | >100 | >100 | NT |
3 | 86.0 ± 9.0 | >100 | NT |
4 | >100 | 79.5 ± 3.8 | NT |
5 | 6.0 ± 1.2 | 9.4 ± 3.8 | >100 |
SAHA | 1.4 ± 0.0 | 2.9 ± 1.1 | 20.8 ± 0.17 |
Next, we performed mechanistic enzyme assays against both total HDACs isolated from cell lysates and the individual recombinant isoform HDAC2, using SAHA as a positive control. When SAHA showed the expected activity with IC50 79.7 nM against HDAC2 (Fig. S1†), none of our synthesized compounds showed significant HDAC2 inhibition at the concentration of 2 μM while the IC50 value of santacruzamate A was reported to be 0.12 nM.18 The assay was repeated three times on different dates, and the results were consistent. We have also double checked the spectrum of 1H NMR of our synthetic santacruzamate A (1a), and verified that our synthetic sample matches the reported data for the natural product (Fig. 3). To exclude a possibility that 1a might be decomposed under the enzymatic assay conditions, a solution of 1a in DMSO was diluted in the buffer employed for the enzymatic assay and incubated for several hours. The sample was finally taken for mass spectroscopy detection, and the clean major peak (m/z 301.0) corresponded to 1a, indicating that 1a tolerated the enzymatic assay conditions (Fig. S2†). These solid results lead us to believe that the original report need to be further reexamined.
While the mechanism of action of our compound 5 does not involve HDAC inhibition, further studies were carried out to profile its biological activity. At a concentration of 5 μM, 5 was able to effectively suppress colony formation of HCT-116 cells in a concentration dependent manner (Fig. 4) and to induce cell cycle arrest at the G2/M phase of HCT-116 cells but not ML-1 cells (Fig. 5).
Fig. 5 The effect of 5 on cell cycle progression of (A) HCT-116 cells and (B) ML-1 cells; (C) and (D) the normalization of the effects above. |
We then further explored whether this inhibition of cell growth and cell cycle arrest by 5 was attributed to the induction of apoptosis. Annexin V/PI double-staining assay was used to study whether 5 could directly induce apoptotic cell death in HCT-116 and ML-1 cells (Fig. 6). The results indicated that 5 significantly increased the percentage of apoptotic cells (Annexin-V-positive) in a dose-dependent manner. No obvious change was observed in necrotic cells (only PI stained) as compared to control at 48 h (data not shown).
Fig. 6 Appotosis of (A) HCT-116 and (B) ML-1 cells induced by 5; (C) and (D) the normalization of the induced appoptosis above. |
It has been widely recognized that increased endogenous reactive oxygen species (ROS) generation can selectively eliminate cancer cells, mainly by raising oxidative stress over the threshold of toxicity to abnormal cancer cells.22 Recently, Schreiber and co-workers have discovered that a natural product piperlongumine selectively killed cancer cells by targeting the stress response to ROS.23 Thus, it was of our interest to examine ROS level in HCT-116 and ML-1 cells treated with 5 (Fig. S3†). The data indicated that a treatment with 5 at 10 μM induced a significant increase in ROS levels both in HCT-116 and ML-1 cells (P < 0.05). Our results implied that selective killing of cancer cells but not normal cells by 5 might result from the ROS generation. Further study to investigate its exact mechanism is under way.
Footnotes |
† Electronic supplementary information (ESI) available: Synthesis and characterisation of the compounds. See DOI: 10.1039/c4ra13889a |
‡ These authors contributed equally to this work. |
This journal is © The Royal Society of Chemistry 2015 |